Athersys, Inc. (ATHX) in Focus: Stock Jumps 8.5% – Tale of the Tape

Zacks

Athersys, Inc. (ATHX) was a big mover last session, as the company saw its shares rise over 8% on the day. Investors reacted positively to the completion of patient enrolment in a phase II clinical study on MultiStem cell therapy for ischemic stroke. This led to far more shares changing hands than in a normal session resulting in solid volume. This reverses the recent trend of the company, as the stock is now trading above the volatile price range of $1.23 to $1.36 since Dec 9, 2014.

None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Athersys currently carries a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Another well-placed stock in the industry is Acorda Therapeutics, Inc. (ACOR), sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

Be the first to comment

Leave a Reply